Evaluation of weekly-reduction regimen of glucocorticoids in combination with cyclophosphamide for anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis in Japanese patients

Yoshinori Matsumoto, Kenei Sada, Fumio Otsuka, Mariko Takano, Noriko Toyota, Koichi Sugiyama, Hiroshi Wakabayashi, Tomoko Kawabata, Hirofumi Makino

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The current therapeutic regimen recommended by the European League against Rheumatism (EULAR) for anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) is continuation of initially administered doses of glucocorticoids (GCs) in combination with cyclophosphamide (CYC) for 1 month followed by gradual tapering. Considering the adverse effects of GCs, another tapering regimen of GCs with CYC, which was characterized by tapering GCs weekly, was reported by the British Society of Rheumatology (weekly-reduction regimen). The aim of the present study is to evaluate the safety and efficacy of this weekly-reduction regimen for Japanese AAV patients in comparison with the monthly-reduction regimen recommended by the EULAR. We retrospectively reviewed medical records of adult patients newly diagnosed with AAV during the period from April 2000 to December 2010. The outcome measures were rates of remission, relapse, infection, and GC-induced diabetes mellitus during the first 12 months. Clinical data in the two groups and categorial variables with a possible relation to the outcomes were compared by using the t test and chi-square test, respectively. Twenty-four patients were enrolled in our study. All of the patients achieved remission, and the rates of relapse during the first 12 months were not statistically different between the two groups (P = 0.16). Patients treated with the weekly-reduction regimen were less liable to have infection (P = 0.03) and impaired glucose tolerance (P = 0.017), compared with those treated with the monthly-reduction regimen. A therapeutic strategy using the weekly-reduction regimen of GCs would be effective and would have fewer side effects than the monthly-reduction regimen.

Original languageEnglish
Pages (from-to)2999-3005
Number of pages7
JournalRheumatology International
Volume32
Issue number10
DOIs
Publication statusPublished - Oct 2012

Fingerprint

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Cyclophosphamide
Glucocorticoids
Vasculitis
Rheumatic Diseases
Recurrence
Glucose Intolerance
Antibodies
Rheumatology
Chi-Square Distribution
Infection
Medical Records
Diabetes Mellitus
Outcome Assessment (Health Care)
Safety
Therapeutics

Keywords

  • Anti-neutrophil cytoplasmic antibody-associated vasculitis
  • Cyclophosphamide
  • Glucocorticoids
  • Retrospective studies

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

Evaluation of weekly-reduction regimen of glucocorticoids in combination with cyclophosphamide for anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis in Japanese patients. / Matsumoto, Yoshinori; Sada, Kenei; Otsuka, Fumio; Takano, Mariko; Toyota, Noriko; Sugiyama, Koichi; Wakabayashi, Hiroshi; Kawabata, Tomoko; Makino, Hirofumi.

In: Rheumatology International, Vol. 32, No. 10, 10.2012, p. 2999-3005.

Research output: Contribution to journalArticle

@article{033222b3b98d4a0ba4c2263fd606ae6a,
title = "Evaluation of weekly-reduction regimen of glucocorticoids in combination with cyclophosphamide for anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis in Japanese patients",
abstract = "The current therapeutic regimen recommended by the European League against Rheumatism (EULAR) for anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) is continuation of initially administered doses of glucocorticoids (GCs) in combination with cyclophosphamide (CYC) for 1 month followed by gradual tapering. Considering the adverse effects of GCs, another tapering regimen of GCs with CYC, which was characterized by tapering GCs weekly, was reported by the British Society of Rheumatology (weekly-reduction regimen). The aim of the present study is to evaluate the safety and efficacy of this weekly-reduction regimen for Japanese AAV patients in comparison with the monthly-reduction regimen recommended by the EULAR. We retrospectively reviewed medical records of adult patients newly diagnosed with AAV during the period from April 2000 to December 2010. The outcome measures were rates of remission, relapse, infection, and GC-induced diabetes mellitus during the first 12 months. Clinical data in the two groups and categorial variables with a possible relation to the outcomes were compared by using the t test and chi-square test, respectively. Twenty-four patients were enrolled in our study. All of the patients achieved remission, and the rates of relapse during the first 12 months were not statistically different between the two groups (P = 0.16). Patients treated with the weekly-reduction regimen were less liable to have infection (P = 0.03) and impaired glucose tolerance (P = 0.017), compared with those treated with the monthly-reduction regimen. A therapeutic strategy using the weekly-reduction regimen of GCs would be effective and would have fewer side effects than the monthly-reduction regimen.",
keywords = "Anti-neutrophil cytoplasmic antibody-associated vasculitis, Cyclophosphamide, Glucocorticoids, Retrospective studies",
author = "Yoshinori Matsumoto and Kenei Sada and Fumio Otsuka and Mariko Takano and Noriko Toyota and Koichi Sugiyama and Hiroshi Wakabayashi and Tomoko Kawabata and Hirofumi Makino",
year = "2012",
month = "10",
doi = "10.1007/s00296-011-2136-z",
language = "English",
volume = "32",
pages = "2999--3005",
journal = "Rheumatology International",
issn = "0172-8172",
publisher = "Springer Verlag",
number = "10",

}

TY - JOUR

T1 - Evaluation of weekly-reduction regimen of glucocorticoids in combination with cyclophosphamide for anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis in Japanese patients

AU - Matsumoto, Yoshinori

AU - Sada, Kenei

AU - Otsuka, Fumio

AU - Takano, Mariko

AU - Toyota, Noriko

AU - Sugiyama, Koichi

AU - Wakabayashi, Hiroshi

AU - Kawabata, Tomoko

AU - Makino, Hirofumi

PY - 2012/10

Y1 - 2012/10

N2 - The current therapeutic regimen recommended by the European League against Rheumatism (EULAR) for anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) is continuation of initially administered doses of glucocorticoids (GCs) in combination with cyclophosphamide (CYC) for 1 month followed by gradual tapering. Considering the adverse effects of GCs, another tapering regimen of GCs with CYC, which was characterized by tapering GCs weekly, was reported by the British Society of Rheumatology (weekly-reduction regimen). The aim of the present study is to evaluate the safety and efficacy of this weekly-reduction regimen for Japanese AAV patients in comparison with the monthly-reduction regimen recommended by the EULAR. We retrospectively reviewed medical records of adult patients newly diagnosed with AAV during the period from April 2000 to December 2010. The outcome measures were rates of remission, relapse, infection, and GC-induced diabetes mellitus during the first 12 months. Clinical data in the two groups and categorial variables with a possible relation to the outcomes were compared by using the t test and chi-square test, respectively. Twenty-four patients were enrolled in our study. All of the patients achieved remission, and the rates of relapse during the first 12 months were not statistically different between the two groups (P = 0.16). Patients treated with the weekly-reduction regimen were less liable to have infection (P = 0.03) and impaired glucose tolerance (P = 0.017), compared with those treated with the monthly-reduction regimen. A therapeutic strategy using the weekly-reduction regimen of GCs would be effective and would have fewer side effects than the monthly-reduction regimen.

AB - The current therapeutic regimen recommended by the European League against Rheumatism (EULAR) for anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) is continuation of initially administered doses of glucocorticoids (GCs) in combination with cyclophosphamide (CYC) for 1 month followed by gradual tapering. Considering the adverse effects of GCs, another tapering regimen of GCs with CYC, which was characterized by tapering GCs weekly, was reported by the British Society of Rheumatology (weekly-reduction regimen). The aim of the present study is to evaluate the safety and efficacy of this weekly-reduction regimen for Japanese AAV patients in comparison with the monthly-reduction regimen recommended by the EULAR. We retrospectively reviewed medical records of adult patients newly diagnosed with AAV during the period from April 2000 to December 2010. The outcome measures were rates of remission, relapse, infection, and GC-induced diabetes mellitus during the first 12 months. Clinical data in the two groups and categorial variables with a possible relation to the outcomes were compared by using the t test and chi-square test, respectively. Twenty-four patients were enrolled in our study. All of the patients achieved remission, and the rates of relapse during the first 12 months were not statistically different between the two groups (P = 0.16). Patients treated with the weekly-reduction regimen were less liable to have infection (P = 0.03) and impaired glucose tolerance (P = 0.017), compared with those treated with the monthly-reduction regimen. A therapeutic strategy using the weekly-reduction regimen of GCs would be effective and would have fewer side effects than the monthly-reduction regimen.

KW - Anti-neutrophil cytoplasmic antibody-associated vasculitis

KW - Cyclophosphamide

KW - Glucocorticoids

KW - Retrospective studies

UR - http://www.scopus.com/inward/record.url?scp=84867894986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867894986&partnerID=8YFLogxK

U2 - 10.1007/s00296-011-2136-z

DO - 10.1007/s00296-011-2136-z

M3 - Article

VL - 32

SP - 2999

EP - 3005

JO - Rheumatology International

JF - Rheumatology International

SN - 0172-8172

IS - 10

ER -